摘要
人表皮生长因子受体-2（Her-2）是一种具有酪氨酸激酶活性的185000的跨膜糖蛋白，在细胞分裂增殖信号跨膜转导中发挥重要功能，最终从多个途径影响肿瘤细胞的生物活动，如肿瘤细胞增殖、黏附、转移和分化等相关基因的调控。研究表明Her-2在胃癌患者中过表达率约12％～35％，是胃癌的预后不良因素，而Her-2单克隆抗体曲妥珠单抗有望成为Her-2过表达胃癌患者的新的标准治疗。
Her-2 （human epidermal growth fact or receptor 2） is a type of 185 kD across the membrane glycoprotein with tyrosine kinase activity, play an important function in the cell divisions across a cell membrane proliferation signal transduction, and finally affect biological activities of tumor cells from multiple ways, such as a tumor cell proliferation and adhesion, transfer and differentiation and other related gene regulation. Recent studies show that Her-2 overexpression rate of gastric cancer patients is about 12% - 35% , and Her-2 is a gastric cancer poor-prognostic factors, while Her-2 monoclonal antibody-Trastuzumab is expected to become a new standard gastric cancer treatment for the patients with Her-2 overexpressed.
出处
《国际肿瘤学杂志》
CAS
2011年第9期687-690,共4页
Journal of International Oncology
关键词
胃肿瘤
靶向治疗
曲妥珠单抗
Stomach neoplasms
Targeted therapy
Trastuzumab
